BOSTON , March 10, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) through theratyping, today announced financial results for the
Nesolicaftor (PTI-428) is the First in a New Class of CFTR Modulators Called Amplifiers Peer-Reviewed Publication Identifies PCBP1 as a Novel Therapeutic Target that Regulates CFTR Biosynthesis BOSTON , Feb. 25, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
Ex Vivo Testing Phase Underway with Tissue Samples Collected from More than 500 Adult CF Patients; Enrollment Target Exceeded Clinical Testing Phase to Begin in 2H 2020 Company Expects CHOICES to Potentially Serve as the Basis for an MAA in 2021 BOSTON , Feb.
Ex vivo Data with Proteostasis' CFTR Modulators in non-F508del and non-G551D CF Genotypes Marks First Step Toward a Personalized Medicine Approach BOSTON , Jan. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the
PTI Triple Combination which Includes First-in-Class Amplifier Outperformed PTI Double Combination of a Proprietary Corrector and Potentiator Launching Two Registrational Studies in 2020 - the MORE Trial in the Common Genotype and the CHOICES Trial in Rare Genotypes Company to Host Conference Call
Ongoing Ex-Vivo Study Supports Initiation of Clinical Trial in 2020 with Potential to Serve as the Basis for an MAA in 2021 BOSTON , Dec. 11, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of
BOSTON , Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
BOSTON , Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
BOSTON , Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
Company Now Expects Phase 2 Top-line Data Later in Q4 of 2019 Instead of Q1 2020 Due to Rapid Enrollment BOSTON , Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking
